Fritextsökning
Innehållstyper
-
Mingling do's and don'ts
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, ...
-
Ambassador program makes MVA big in Japan
The first ambassadors of the Medicon Valley Ambassador Programme have only worked in each other's countries for six months. But they have already made a signifi...
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Diamyd förlikar i licenstvist
Ger University of Florida en del av ersättningen de fick från affären med Ortho-McNeil-Janssen.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Grape extract kills cancer cells
Grapes contain potentially beneficial chemicals that can destroy cancer cells, a new research proves.
-
Infidelity produces faster sperms
Until now, it has been difficult to prove that fast-swimming sperms have an advantage when it comes to fertilizing an egg.
-
Säkerhetsbrister på barnsjukhus
Knäckte lösenorden till skyddade dokument från prövningar
-
Sanionas kokainstudie inledd
Bioteknikföretagets samarbetspartner TRC har påbörjat rekrytering till studien om kokainberoende.
-
Schizophrenia and bipolar disorder are relatives
Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet.
-
EMA tillsätter expertgrupp mot Zika
Erbjuder rådgivning kring vetenskapliga och regulatoriska frågor till bolag som utvecklar läkemedel och vaccin mot viruset.
-
Academy for a new turn at work
Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.
-
Nytt namn i Symphogens ledning
Adriann Sax har utsetts till affärschef på det danska företaget.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Här testas tekniker för framtidens tillverkning
Biologiska läkemedel är världens snabbast växande klass av läkemedel. Sverige vill hänga på. Men då räcker det inte med innovativa molekyler. Vi måste bli bra p...
-
Swedish cancer therapy granted
Pledpharma, Linköping University and Ryhov County Hospital receive a research grant from the Research Council FORSS to conduct clinical studies in cancer patients.
-
Satsar på tidig forskning
Tillsammans med tre universitet skapar Astrazeneca, GSK och Johnson and Johnson en fond för utveckling av prekliniska projekt.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
535 miljoner till regenerativ medicin
Knut och Alice Wallenbergs Stiftelse finansierar ett nytt forskningscentrum i Lund.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Sprint får ny vetenskaplig rådgivare
Cancerforskaren Ravi Amaravadi från USA ska hjälpa bolaget till klinisk fas.
-
Första Crispr-bolaget till börsen
Editas Medicine blir det första bolaget på börsen med fokus på det omtalade genmodifieringsverktyget Crispr/Cas9.
-
Positive combined cancer therapy
Topotarget announces positive data with new treatment against colorectal cancer.
BREAKING